FDA Clears Personalized Neuromodulation System for PTSD Treatment
Key Clinical Summary
- The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s Magnetic EEG-guided Resonance Therapy (MeRT) System, a personalized, biomarker-guided neuromodulation technology approved for the treatment of posttraumatic stress disorder (PTSD).
- FDA clearance was supported by a double-blinded, randomized, controlled multisite clinical trial conducted in partnership with the Texas A&M Health Institute of Biosciences and Technology.
- The study demonstrated significant and clinically meaningful reductions in PTSD symptom severity following treatment with the MeRT System.
The US FDA has cleared Wave Neuroscience’s MeRT System, a personalized, biomarker-guided neuromodulation technology approved for the treatment of PTSD. This marks the first FDA-cleared personalized, biomarker-guided neuromodulation platform for the disorder, according to an announcement released by the manufacturer.
Study Findings
The FDA decision was based on a double-blinded, randomized, controlled multisite trial (NCT02990793) designed to evaluate the safety and effectiveness of MeRT for PTSD. The study was conducted by investigators at the Texas A&M Health Institute of Biosciences and Technology.
According to the news release, trial results demonstrated “significant and clinically meaningful reductions” in PTSD symptom severity following treatment with the MeRT System, though specific efficacy data were not disclosed.
MeRT leverages artificial intelligence–augmented electroencephalography (EEG)-based biomarker analysis with individualized neuromodulation protocols. The system uses a patient’s own brain activity data to guide treatment delivery, distinguishing it from traditional neuromodulation approaches that use standardized treatment parameters.
The technology previously received FDA Breakthrough Device designation in 2024 for its potential to address unmet needs in PTSD care.
Clinical Implications
PTSD affects millions worldwide, including veterans, active-duty military personnel, first responders, trauma survivors, and civilians. Despite available psychotherapies and pharmacologic treatments, many patients continue to experience persistent symptoms, highlighting an ongoing unmet clinical need.
The FDA clearance introduces a personalized, noninvasive treatment option that uses objective neurophysiologic biomarkers to inform care. By integrating EEG-derived brain activity measurements into treatment planning, the system aims to tailor neuromodulation to each patient’s unique neural activity patterns.
For clinicians, the clearance may signal growing regulatory acceptance of precision psychiatry approaches that incorporate biological measurements into mental health treatment. The manufacturer also indicated that the decision could facilitate physician adoption and broader integration of biomarker-guided interventions into clinical practice.
Expert Commentary
"Many PTSD patients continue to struggle despite conventional therapies and pharmacologic interventions," said Erik Won, MD, Chief Medical Officer, Wave Neuroscience. "This clearance supports the advancement of a non-invasive treatment approach designed to align therapy with each patient's individual brain physiology.”
Ken Ramos, MD, PhD, Distinguished Professor and Executive Director of the Texas A&M Health Institute of Biosciences and Technology, Texas, added that the availability of this personalized technology “represents a significant advancement in our ability to overcome the extensive heterogeneity in clinical presentation of patients with PTSD.”
